Biotechnology
Compare Stocks
2 / 10Stock Comparison
NKTX vs CELC
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
NKTX vs CELC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $223M | $5.66B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-103M | $-163M |
| Total Debt | $80M | $98M |
| Cash & Equiv. | $28M | $23M |
NKTX vs CELC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 20 | May 26 | Return |
|---|---|---|---|
| Nkarta, Inc. (NKTX) | 100 | 12.2 | -87.8% |
| Celcuity Inc. (CELC) | 100 | 2466.2 | +2366.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NKTX vs CELC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NKTX carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- EPS growth 33.3%
- Lower volatility, beta 2.07, Low D/E 19.7%, current ratio 14.45x
- 8.0% revenue growth vs CELC's -73.2%
CELC is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.71
- 8.1% 10Y total return vs NKTX's -93.4%
- Beta 1.71, current ratio 7.71x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.0% revenue growth vs CELC's -73.2% | |
| Quality / Margins | 3.9% margin vs CELC's 0.6% | |
| Stability / Safety | Beta 1.71 vs NKTX's 2.07 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +11.8% vs NKTX's +68.4% | |
| Efficiency (ROA) | -24.0% ROA vs CELC's -58.0%, ROIC -24.3% vs -50.3% |
NKTX vs CELC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
NKTX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NKTX and CELC operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$113M | -$159M |
| Net IncomeAfter-tax profit | -$103M | -$163M |
| Free Cash FlowCash after capex | -$94M | -$145M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +25.6% | -31.4% |
Valuation Metrics
Evenly matched — NKTX and CELC each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $223M | $5.7B |
| Enterprise ValueMkt cap + debt − cash | $275M | $5.7B |
| Trailing P/EPrice ÷ TTM EPS | -1.97x | -46.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.52x | 44.60x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
NKTX leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
NKTX delivers a -30.4% return on equity — every $100 of shareholder capital generates $-30 in annual profit, vs $-179 for CELC. NKTX carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to CELC's 0.85x. On the Piotroski fundamental quality scale (0–9), NKTX scores 4/9 vs CELC's 1/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -30.4% | -179.0% |
| ROA (TTM)Return on assets | -24.0% | -58.0% |
| ROICReturn on invested capital | -24.3% | -50.3% |
| ROCEReturn on capital employed | -30.6% | -58.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.20x | 0.85x |
| Net DebtTotal debt minus cash | $52M | $75M |
| Cash & Equiv.Liquid assets | $28M | $23M |
| Total DebtShort + long-term debt | $80M | $98M |
| Interest CoverageEBIT ÷ Interest expense | — | -5.02x |
Total Returns (Dividends Reinvested)
CELC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CELC five years ago would be worth $48,161 today (with dividends reinvested), compared to $1,139 for NKTX. Over the past 12 months, CELC leads with a +1184.0% total return vs NKTX's +68.4%. The 3-year compound annual growth rate (CAGR) favors CELC at 140.6% vs NKTX's -11.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +68.4% | +30.0% |
| 1-Year ReturnPast 12 months | +68.4% | +1184.0% |
| 3-Year ReturnCumulative with dividends | -31.5% | +1292.0% |
| 5-Year ReturnCumulative with dividends | -88.6% | +381.6% |
| 10-Year ReturnCumulative with dividends | -93.4% | +814.7% |
| CAGR (3Y)Annualised 3-year return | -11.9% | +140.6% |
Risk & Volatility
CELC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CELC is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than NKTX's 2.07 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.07x | 1.71x |
| 52-Week HighHighest price in past year | $3.65 | $151.02 |
| 52-Week LowLowest price in past year | $1.63 | $9.51 |
| % of 52W HighCurrent price vs 52-week peak | +86.3% | +86.6% |
| RSI (14)Momentum oscillator 0–100 | 66.9 | 63.4 |
| Avg Volume (50D)Average daily shares traded | 802K | 800K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates NKTX as "Buy" and CELC as "Buy". Consensus price targets imply 585.7% upside for NKTX (target: $22) vs -4.6% for CELC (target: $125).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $21.60 | $124.75 |
| # AnalystsCovering analysts | 12 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
NKTX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CELC leads in 2 (Total Returns, Risk & Volatility). 1 tied.
NKTX vs CELC: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NKTX or CELC a better buy right now?
Analysts rate Nkarta, Inc.
(NKTX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NKTX or CELC?
Over the past 5 years, Celcuity Inc.
(CELC) delivered a total return of +381. 6%, compared to -88. 6% for Nkarta, Inc. (NKTX). Over 10 years, the gap is even starker: CELC returned +814. 7% versus NKTX's -93. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NKTX or CELC?
By beta (market sensitivity over 5 years), Celcuity Inc.
(CELC) is the lower-risk stock at 1. 71β versus Nkarta, Inc. 's 2. 07β — meaning NKTX is approximately 21% more volatile than CELC relative to the S&P 500. On balance sheet safety, Nkarta, Inc. (NKTX) carries a lower debt/equity ratio of 20% versus 85% for Celcuity Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — NKTX or CELC?
On earnings-per-share growth, the picture is similar: Nkarta, Inc.
grew EPS 33. 3% year-over-year, compared to -5. 2% for Celcuity Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NKTX or CELC?
Nkarta, Inc.
(NKTX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Celcuity Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKTX leads at 0. 0% versus 0. 0% for CELC. At the gross margin level — before operating expenses — NKTX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NKTX or CELC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NKTX or CELC better for a retirement portfolio?
For long-horizon retirement investors, Celcuity Inc.
(CELC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+814. 7% 10Y return). Nkarta, Inc. (NKTX) carries a higher beta of 2. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CELC: +814. 7%, NKTX: -93. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NKTX and CELC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.